At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 751 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide in Adults Who Have Obesity or Overweight With Weight Related Comorbidities
In Brief
A Phase 3 clinical trial evaluating Tirzepatide and Semaglutide for Obesity and Overweight. Completed, enrolled 751 participants across 32 sites in 2 countries.
Detailed Summary
The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Overweight
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202420252026
First PostedApr 2023
Enrollment StartApr 2023
Primary CompletionNov 2024
TodayJul 2026
First PostedApr 21, 2023
Enrollment StartApr 21, 2023
Primary CompletionNov 13, 2024
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 3.2 years ago
Interventions
Tirzepatidedrug
Administered SC
Semaglutidedrug
Administered SC